Meeting
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.
Authors
Zhong Zheng
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Zhong Zheng , Huilai Zhang , Keshu Zhou , Hui Zhou , Li Zhang , Caixia Li , Min Zhou , Wenbin Qian , Zhiming Li , Qingyuan Zhang , Ying Cheng , Peng Liu , Zhenyu Li , Liping Su , Fei Li , Xiuhua Sun , Jingwen Wang , Yuhuan Gao , Xielan Zhao , Weili Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04298879
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7574)
DOI
10.1200/JCO.2022.40.16_suppl.7574
Abstract #
7574
Poster Bd #
226
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.
First Author: Andrew David Zelenetz
Poster
2019 ASCO Annual Meeting
ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).
First Author: Michael Dickinson
Poster
2022 ASCO Annual Meeting
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.
First Author: Pier Luigi Zinzani
Poster
2022 ASCO Annual Meeting
Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.
First Author: Lin Gui